Yuki Kato

11PUBLICATIONS
226CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Regenerative medicine (incl. stem cells)Human biophysicsExercise physiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jul 02, 2026
The Lowest PSA Level Achieved Before CRPC Predicts Abiraterone Response But Not Enzalutamide Response in Metastatic CRPC.

|May 20, 2026
Efficacy and Safety of Enzalutamide and Abiraterone in CRPC Patients With a History of Other Cancers: A Sub-Analysis of the ENABLE Study for PCa.

|Oct 29, 2025
Human Papillomavirus Prevalence in the Prostate and Seminal Vesicles: Does This Virus Have an Etiological Role in the Development of Prostate Cancer?

Rei Shinzawa, Kazuyoshi Shigehara, Hiroki Nakata

|Oct 22, 2024
Testosterone Replacement Therapy Can Improve a Biomarker of Liver Fibrosis in Hypogonadal Men: A Subanalysis of a Prospective Randomized Controlled Study in Japan (EARTH Study).

Kazuyoshi Shigehara, Yuki Kato, Rei Shinzawa

|Apr 18, 2024
Real-world short-term outcomes of prostate urethral lift in Japan: A prospective cohort study.

Yuki Kato, Aya Kamatani, Kazuyoshi Shigehara

|Feb 10, 2024
Enzalutamide versus Abiraterone Plus Prednisolone for Nonmetastatic Castration-Resistant Prostate Cancer: A Sub-Analysis from the ENABLE Study for PCa.

Koji Mita, Kouji Izumi, Akihiro Goriki

Pageof 2

Frequent Collaborators

6 joint publications

Atsushi Mizokami

5 joint publications

Kazuyoshi Shigehara

5 joint publications

Kouji Izumi

3 joint publications

Shohei Kawaguchi